Landerlan Paraguay - Official Website
Español English

DECALAND DEPOT 200mg/5mL

DECALAND - Depot
Nandrolone decanoate
I.V.
ADULT USE

FORMULA

Each ml contains:
Nandrolone decanoate ………………………………………………………. 200 mg
Excipients…………………………………………………………………….. q.s.

DESCRIPTION

Decaland depot is an injectable anabolic preparation. The pharmacologically active substance is nandrolone. The decanoate ester provides the preparation a duration of action of approximately 3 weeks after the injection. Nandrolone is chemically related to the male hormone.

Compared to testosterone it has a pronounced anabolic activity and a reduced androgenic activity. This has been demonstrated in bioassays in animals and clarified through studies of receptor binding. The low androgenicity of nandrolone has been confirmed in clinical use.

Nandrolone decanoate has been shown to positively influence calcium metabolism and increase bone mass in osteoporosis. In women with disseminated breast carcinoma, it has been reported to produce objective regressions for several months. Plus, nandrolone has a nitrogen- saving action.

This effect on the protein metabolism has been proved in metabolic studies and is therapeutically used in conditions where there is a shortage of proteins, e.g., during chronic debilitating diseases, after major surgery and severe trauma.

In these conditions nandrolone serves as an adjuvant supporting specific treatments and dietary measures, as well as parenteral nutrition. To recommended doses androgenic effects (such as virilization) are relatively rare. Nandrolone lacks the C17 alpha-akil group associated with the development of hepatic dysfunction and cholestasis.

Nandrolone decanoate is slowly released from the site of injection into the blood with a half -live of 6 days. In serum, the ester is rapidly hydrolysed in nandrolone with a half-life of an hour or less.

Half-life for the combined process of hydrolysis of the nandrolone decanoate and distribution and clearance of nandrolone is 4.3 hours.

Nandrolone is metabolized by the liver.

19-norandrosterone, 19-norethiocholanolone and 19- norepiandrosterone have been identified as metabolites in urine. It is not known if these metabolites have some pharmacological action.

INDICATIONS

To promote protein anabolism.
Osteoporosis
For palliative treatment of selected cases of disseminated breast carcinoma in women.

As adjuvant in specific therapeutic and dietary measures in pathological conditions characterized by a negative nitrogen balance.

Remark: For optimal therapeutic effect it is necessary to administer adequate amounts of vitamins, minerals and proteins on a high-calory diet.

ADVERSE REACTIONS AND SIDE EFFECTS

High doses, long-term treatment and/or too frequent administration can cause:

- Virilization in women who are sensitive as hoarse voice, acne, hirsutism and increased libido; in prepubertal boys as increased frequency of erections and phallic enlargement and in girls as increased pubic hair and clitorial hypertrophy. Hoarseness can be the first symptom of vocal change which can lead to sometimes irreversible hoarseness.
- Amenorrhea.
- Inhibition of spermatogenesis
- Premature epiphyseal closure
- Liquid retention

CONTRAINDICATIONS

Pregnancy. Known or suspected prostate carcinoma or breast carcinoma in men. This drug should not be used during pregnancy because of the possibility of fetal masculinization. There are no data available about the use of this drug during lactation to establish a potential harm to the baby or a probable influence on milk production.

PRECAUTIONS AND WARNINGS (regarding effects related to carcinogenicity, mutagenicity, teratogenicity and fertility)

If signs of virilization are developed discontinuation of treatment should be considered, preferably after consultation with the patient.

Patients with any of these conditions should be monitored: latent or overt cardiac failure, renal dysfunction, hipertension or migraine (or history of these conditions) since anabolic steroids can include liquid retention.

Incomplete statural gowth since anabolic steroids in high dosis can accelerate epiphyseal closure.

Metastases in spinal chord or breast carcinoma. In these patients hypercalcemia can be spontaneously developed in both cases and as a result of a therapy with anabolic steroids. The latter may be indicative of a positive tumoral response to a hormone treatment.

However, hypercalcemia must be primarily treated adequately and afterwards, the hormone therapy might be resumed once the normal level of calcium is restored.

Hepatic failure.

Misuse of anabolic steroids to enhance performance in sport carries serious health risks, so it should be discouraged.

DRUG INTERACTIONS AND OTHER TYPES OF INTERACTION

Anabolic steroids can improve glucose tolerance and reduce the need of insulin or other antidiabetic drugs in diabetic patients.

DOSAGE

It should be administered by deep intramuscular injection.

Osteoporosis: 50 mg every three weeks

As palliative treatment in selected cases of disseminated breast carcinoma in women: 50 mg every 2-3 weeks.

As adjuvant in specific therapies and dietary measures in pathological conditions characterized by a negative nitrogen balance: 25-50 mg every three weeks.

OVERDOSE OR ACCIDENTAL INTAKE

Acute toxicity of nandrolone decanoate in animales is very low. There are no reports of acute overdose with nandrolone in human beings.

PACKAGING

Box with ampoule x 5 ml

Keep at a temperature below 25º C in a dry place.
Keep out of reach of children.

Sale only with Prescription.
Made in Paraguay